Loading data for VALN — first visit, this takes a few seconds.
Valneva SE (VALN)
NasdaqGS: VALN
· Real-Time Price · USD
6.75
-0.21 (-3.02%)
At close: Aug 24, 2026, 8:00 PM
6.71
-0.59%
After-hours: 7:31 PM
The price, the headline numbers and the latest news, in one place.
Valneva SE (VALN) Stock Price, Analysis & Data
-3.02% (1D)
No data available
| Bid | 6.91 |
| Market Cap | 640.06M |
| Revenue (ttm) | 142.94M |
| Net Income (ttm) | -157.65M |
| 1.35 | |
| -2.1 | |
| n/a | |
| 5.67 | |
| P/B (ttm) | 6.82 |
| P/S (ttm) | 4.48 |
| Earnings Date | Mar 17, 2027 |
| Ask | 6.8 |
| Volume | 21,945 |
| Avg. Volume (20D) | 77,003 |
| Open | 6.68 |
| Previous Close | 6.96 |
| Day's Range | 6.60 - 6.80 |
| 52-Week Range | 4.75 - 12.23 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VALN
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bac...
Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2021
Employees 620
Stock Exchange NasdaqGS
Ticker Symbol VALN
Website https://valneva.com
Financial Performance
In 2025, Valneva SE's revenue was 174.66M, an increase of 3% compared to the previous year's 169.58M. Earnings were -115.19M, an increase of 840.57%.
Financial StatementsEarnings Surprise
Valneva SE has released their quarterly earnings on Aug 12, 2026:
- Revenue of $30.9M misses estimates by $0, with -37.23% YoY decline.
- EPS of -0.4 misses estimates by -0.32, with -150.00% YoY decline.
Valneva SE is scheduled to release its earnings on Mar 17, 2027, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2